State abortion bans may limit access to drug used to treat lupus and cancer
Pharmacists may be hesitant to fill methotrexate prescriptions.
State-level restrictions on abortion may be blocking some patients' access to methotrexate, a drug used to treat several autoimmune diseases, including lupus and rheumatoid arthritis, as well as some cancers, such as breast and lung cancers.
That's because, in addition to these diseases, methotrexate (also known by the brand names Otrexup (PF), Xatmep and Trexall) is sometimes used to treat ectopic pregnancy, a condition in which the fertilized egg implants outside the uterus. An ectopic pregnancy never produces a viable, full-term fetus and is life-threatening to the pregnant person if not immediately terminated. In some cases, the pregnancy can be terminated with an injection of methotrexate, which stops the growth of the embryo by preventing cell division.
Following the Supreme Court's decision to overturn Roe v. Wade, about 15 states immediately moved to ban or severely restrict abortion, including the prescription and use of medications capable of ending a pregnancy, The Washington Post reported. In at least some of these states, these restrictions have already caused roadblocks for patients seeking methotrexate for other uses, and some patients shared their experiences on social media. For now, these reports are anecdotal, so it's unclear how many patients have been affected and where they're all located.
One Twitter user who reportedly takes methotrexate for rheumatoid arthritis said, "I was told today I could not be prescribed it any longer as I am viably fertile and it is a medication that can be used for abortion." A person with lupus said, "I received an email from my rheumatologist today that they are stopping all refills of methotrexate because it is considered an abortifacient."
Related: Roe v. Wade FAQ: What if abortion rights law gets overturned?
"We have heard of a handful of cases of patients being completely denied [prescriptions] simply because they're of childbearing age," Steven Newmark, director of policy and chief legal officer at the Global Healthy Living Foundation, a Nyack, New York-based nonprofit that supports people with chronic illnesses, told Time. They've also heard of cases in which patients have been told by their pharmacist to "go back to their doctor, or the pharmacist has to check with the doctor, or the doctor is being wary and more reluctant" to prescribe methotrexate, he said.
The Lupus Foundation of America, Crohn's & Colitis Foundation and Arthritis Foundation have issued statements about the emerging issue, and the latter group set up a hotline (1-800-283-7800) for patients who have had problems accessing methotrexate. In addition, the American College of Rheumatology announced that it had assembled a task force to investigate the scope of the problem and has asked that patients who experience challenges in filling their prescriptions email email@example.com with details.
Patients in Texas faced similar challenges even before Roe v. Wade was overturned, due to the existing state laws that had already restricted access to abortions, Slate reported in May. Under a Texas law called S.B. 4, methotrexate is specifically listed as an "abortion-inducing drug," and as such, the law requires that those who dispense the drug follow certain protocols or else risk a felony charge. Because of this, pharmacists became hesitant about filling any methotrexate prescriptions, regardless of their purpose.
Besides lupus, rheumatoid arthritis, cancer and ectopic pregnancy, methotrexate can be used to treat psoriasis, Crohn's disease and multiple sclerosis, according to the National Library of Medicine's MedlinePlus. It's also used for psoriatic arthritis and juvenile idiopathic arthritis (JIA), according to the Arthritis Foundation. "In some cases, such as toddlers with JIA, methotrexate can be life-changing, getting the disease into remission so the child can live a full and pain-free life," the statement said.
Originally published on Live Science.
Live Science newsletter
Stay up to date on the latest science news by signing up for our Essentials newsletter.
Nicoletta Lanese is the health channel editor at Live Science and was previously a news editor and staff writer at the site. She holds a graduate certificate in science communication from UC Santa Cruz and degrees in neuroscience and dance from the University of Florida. Her work has appeared in The Scientist, Science News, the Mercury News, Mongabay and Stanford Medicine Magazine, among other outlets. Based in NYC, she also remains heavily involved in dance and performs in local choreographers' work.
By Kiley Price